this Site does not mention Rose but does say that Hruby sold 47000 shares from Jun 3 through June 5. He sold 68403 shares in the last quarter and he now owns only 47124 shares. He sells a lot but surprised he only owns 47 thousand shares. I found nothing on Rose. Also looked for a form 4. Please provide me with a link on Rose.
what site did you find these trades, both of June 5 2015. I was not aware that it was available that fast. Nasdaq has the previous six trades, Mcandrews bought 5 times and Hruby sold 68,403. Guess Hruby had to pay his ex. I think they only update quarterly.
drod, does your mother know that you are on her computor again?
Soon I hope. Would be interesting to hear from CS Mclemore, does this favor SIGA regarding reliance damages?
Do you really believe that SIGA execs and Pereleman and Co violated any sec rules? They are way to smart for that, maybe some legal manuvering which is being done now with SIGA stock prices but not a violation. Just a ploy from PIP to try and make them look bad. This is going back to the bankruptcy court and PIP is trying to plant some more garbage to sway the bkrupcy judge.
Dr Rose once called compound St 669 his silver bullet?
Another Rose failure? I am sure that he is a puppet for Perleman but he has been useless. This is an interesting 2014 publication regarding ST 669.
Antimicrob Agents Chemother. 2014 Jul;58(7):3860-6. doi: 10.1128/AAC.02064-13. Epub 2014 Apr 28.
The broad-spectrum antiviral compound ST-669 restricts chlamydial inclusion development and bacterial growth and localizes to host cell lipid droplets within treated cells.
Sandoz KM1, Valiant WG1, Eriksen SG1, Hruby DE2, Allen RD 3rd2, Rockey DD3.
Novel broad-spectrum antimicrobials are a critical component of a strategy for combating antibiotic-resistant pathogens. In this study, we explored the activity of the broad-spectrum antiviral compound ST-669 for activity against different intracellular bacteria and began a characterization of its mechanism of antimicrobial action. ST-669 inhibits the growth of three different species of chlamydia and the intracellular bacterium Coxiella burnetii in Vero and HeLa cells but not in McCoy (murine) cells. The antichlamydial and anti-C. burnetii activity spectrum was consistent with those observed for tested viruses, suggesting a common mechanism of action. Cycloheximide treatment in the presence of ST-669 abrogated the inhibitory effect, demonstrating that eukaryotic protein synthesis is required for tested activity. Immunofluorescence microscopy demonstrated that different chlamydiae grow atypically in the presence of ST-669, in a manner that suggests the compound affects inclusion formation and organization. Microscopic analysis of cells treated with a fluorescent derivative of ST-669 demonstrated that the compound localized to host cell lipid droplets but not to other organelles or the host cytosol. These results demonstrate that ST-669 affects intracellular growth in a host-cell-dependent manner and interrupts proper development of chlamydial inclusions, possibly through a lipi droplet dependent process
tween, this is a $100 contract follow up that Barda said from the beginning that they were going to have two smalpox cures. Dont think Siga can protest this order. It also allows that they can expand to $435 Mll if they exercise all options. Probably not a good time for this to happen, guess Chimerix finally got their product to to point of acceptance Yahoo will not let me post the link but you can find it under Fedbzopps,gov solicitation #ntent-2015-1-SPXAV
Pretty sure both SIGA and PIP filed some time ago, how long does the SP have to decide if they review again or reject? Anyone know if this decision has been made?
my attorney says that the interest stopped accruing on the day that Siga filed Chapter 11. Maybe someone here can confirm if that is correct.
This Judgment, if the SC agrees or disagrees with Siga ends the relationship. PIP has no interest in Future Sigas good fortunes.
so you got yourself another handle Zackdrod regarding Rose, Ron Perelman will keep Rose as long as he wants to, McAndrews and Perelman has purchased over 600,000 shares since Sept. He owns more than all us together. So, getting tired of you saying we need to vote him out.
In footmark 1 parsons states that Siga submitted an amount of $105,111,000 as the approximate sum by their calculations so with only 8 ml in dispute I expect Siga is delighted with this opinion and will probably continue on appeal for reduction of the prejudgment interest.
For the foregoing reasons, I hereby direct PharmAthene to submit, within five business days, a revised Proposed Judgment that reflects the rulings in this letter, including an award of $113,116,985 in contract expectation damages.5 Pre-judgment interest on that amount shall be calculated in accordance with the rate data and methodology Baliban used in his most recent report.6
IT IS SO ORDERED